Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

1.1K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.1K
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

1.1K
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
1.1K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

646
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
646
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

1.0K
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
1.0K
Drug Therapy01:28

Drug Therapy

361
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
361
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.1K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence and determinants of selected modifiable risk factors of cardiovascular diseases among male prisoners of Karachi.

International journal of prison health·2025
Same author

Awareness of Genetic Testing and Its Impact on Changing Behavior among General Population of the USA: Health Information National Trends Survey (HINTS 2022).

Lifestyle genomics·2025
Same author

Emerging trends and future challenges of advanced 2D nanomaterials for combating bacterial resistance.

Bioactive materials·2024
Same author

Self-assembled and Zn(II)-coordinated dipeptide nanoparticles with membrane-rupturing action on bacteria.

Applied microbiology and biotechnology·2023
Same author

Frequency and risk factors of musculoskeletal disorders in high risk occupation workers in Urban, Karachi.

JPMA. The Journal of the Pakistan Medical Association·2023
Same author

Copper-based nanoparticles against microbial infections.

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology·2023

Related Experiment Video

Updated: Mar 11, 2026

Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice
04:44

Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice

Published on: February 16, 2024

2.3K

Depot antipsychotics: Where do we stand?

Ahsan Y Khan1, Salman Salaria, Muhammad Ovais

  • 1Armor Correctional Health Services, Inc., Oklahoma City, OK USA, Department of Psychiatry and Behavioral Neurosciences, Saint Louis University, St. Louis, MO USA.

Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists
|December 1, 2016
PubMed
Summary
This summary is machine-generated.

Depot antipsychotics improve medication adherence in schizophrenia patients, reducing risks of relapse, hospitalization, and incarceration. Evidence supports their use as a first-line treatment option.

More Related Videos

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents
08:38

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents

Published on: September 1, 2011

76.0K
Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

4.8K

Related Experiment Videos

Last Updated: Mar 11, 2026

Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice
04:44

Author Spotlight: Studying Drug Impacts on Brain Signals Using Dual LFP Recording Protocol in Mice

Published on: February 16, 2024

2.3K
Habituation and Prepulse Inhibition of Acoustic Startle in Rodents
08:38

Habituation and Prepulse Inhibition of Acoustic Startle in Rodents

Published on: September 1, 2011

76.0K
Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

4.8K

Area of Science:

  • Psychiatry
  • Pharmacology

Background:

  • Medication nonadherence is a significant challenge in schizophrenia management.
  • Depot antipsychotics were developed to address adherence issues.
  • Physician reluctance to use depot antipsychotics as a first-line treatment persists despite their availability.

Purpose of the Study:

  • To review the latest information on depot antipsychotic use in schizophrenia treatment.
  • To present evidence supporting the use of depot antipsychotics as a first-line therapy.
  • To analyze the development and evolution of depot antipsychotics.

Main Methods:

  • Systematic review of four key schizophrenia studies: CATIE, EUFEST, ACLAIMS, and PRIDE.
  • Aggregate analysis of the history and utilization of depot antipsychotics.
  • Summarization of clinical trial findings related to depot antipsychotic efficacy and adherence.

Main Results:

  • Oral antipsychotic discontinuation rates were high (74% within 6 months in CATIE, 42% within 12 months in EUFEST).
  • The PRIDE study showed a 43% higher risk of first hospitalization or arrest in the oral antipsychotic group compared to the depot group.
  • ACLAIMS found no significant difference in efficacy failure rates between specific depot formulations.

Conclusions:

  • Clinical evidence supports depot antipsychotic formulations as a first-line treatment for schizophrenia.
  • Improved adherence with depot antipsychotics can lower the risk of relapse, suicide, rehospitalization, and incarceration.
  • Depot antipsychotics represent a valuable therapeutic option for enhancing patient outcomes in schizophrenia.